Incretin action maintains insulin secretion, but not hepatic insulin action, in people with impaired fasting glucose

Diabetes Research and Clinical Practice

Volumn 90, Issue 1, 2010, Pages 87-94

  Perreault, Leigh ^a   Man, Chiara Dalla ^b   Hunerdosse, Devon M ^a   Cobelli, Claudio ^b   Bergman, Bryan C ^a  

^a UNIVERSITY OF COLORADO   (United States)

^b UNIVERSITY OF PADOVA   (Italy)

Author keywords

Beta cell; GLP 1; Liver; Pre diabetes; Stable isotopes

Indexed keywords

C PEPTIDE; DIPEPTIDYL PEPTIDASE IV; FATTY ACID; GLUCAGON LIKE PEPTIDE 1; GLUCOSE; INCRETIN; INSULIN; SITAGLIPTIN;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG EFFECT; DRUG HYPERSENSITIVITY; DRUG MECHANISM; DRUG TOLERABILITY; ENZYME INHIBITION; FEMALE; GLUCONEOGENESIS; GLUCOSE BLOOD LEVEL; HORMONE ACTION; HUMAN; IMPAIRED GLUCOSE TOLERANCE; INSULIN BLOOD LEVEL; INSULIN RELEASE; INSULIN RESISTANCE; INSULIN SENSITIVITY; INTRAVENOUS GLUCOSE TOLERANCE TEST; MALE; ORAL GLUCOSE TOLERANCE TEST; PANCREAS ISLET BETA CELL; PANCREAS ISLET CELL FUNCTION; PATIENT COMPLIANCE; PROTEIN BLOOD LEVEL; PROTEIN FUNCTION; TREATMENT DURATION;

AGED; BLOOD GLUCOSE; BODY MASS INDEX; C-PEPTIDE; DIPEPTIDYL-PEPTIDASE IV INHIBITORS; FEMALE; GLUCAGON-LIKE PEPTIDE 1; GLUCOSE; GLUCOSE TOLERANCE TEST; HUMANS; HYPERGLYCEMIA; INCRETINS; INSULIN; INSULIN RESISTANCE; INSULIN-SECRETING CELLS; LIVER; MALE; MIDDLE AGED; PYRAZINES; SEVERITY OF ILLNESS INDEX; TRIAZOLES;

EID: 77956184155     PISSN: 01688227     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.diabres.2010.06.012     Document Type: Article

References (29)

1. Buchanan T.A., Xiang A.H., Peters R.K. Preservation of pancreatic beta-cell function and prevention of type 2 diabetes by pharmacological treatment of insulin resistance in high-risk Hispanic women. Diabetes 2002, 51:2796-2803.
2. Gerstein H.C., Yusuf S., Bosch J. Effect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose: a randomised controlled trial. Lancet 2006, 368:1096-1105.
3. Knowler W.C., Barrett-Connor E., Fowler S.E. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 2002, 346:393-403.
4. Tuomilehto J., Lindstrom J., Eriksson J.G. Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. N Engl J Med 2001, 344:1343-1350.
5. Abdul-Ghani M.A., Jenkinson C.P., Richardson D.K., Tripathy D., DeFronzo R.A. Insulin secretion and action in subjects with impaired fasting glucose and impaired glucose tolerance: results from the Veterans Administration Genetic Epidemiology Study. Diabetes 2006, 55:1430-1435.
6. Bock G., Dalla Man C., Campioni M. Pathogenesis of pre-diabetes: mechanisms of fasting and postprandial hyperglycemia in people with impaired fasting glucose and/or impaired glucose tolerance. Diabetes 2006, 55:3536-3549.
7. Perreault L., Bergman B.C., Playdon M.C., Dalla Man C., Cobelli C. Eckel RH. Impaired fasting glucose with or without impaired glucose tolerance: progressive or parallel states of pre-diabetes?. Am J Physiol Endocrinol Metab 2008, 295:E428-E435.
8. Weyer C., Bogardus C., Pratley R.E. Metabolic characteristics of individuals with impaired fasting glucose and/or impaired glucose tolerance. Diabetes 1999, 48:2197-2203.
9. Balas B., Baig M.R., Watson C. The dipeptidyl peptidase IV inhibitor vildagliptin suppresses endogenous glucose production and enhances islet function after single-dose administration in type 2 diabetic patients. J Clin Endocrinol Metab 2007, 92:1249-1255.
10. Elahi D., Egan J.M., Shannon R.P. GLP-1 (9-36) amide, cleavage product of GLP-1 (7-36) amide, is a glucoregulatory peptide. Obesity (Silver Spring) 2008, 16:1501-1509.
11. Genuth S., Alberti K.G., Bennett P. Follow-up report on the diagnosis of diabetes mellitus. Diabetes Care 2003, 26:3160-3167.
12. Bergman R.N., Watanabe R.M., Rebrin K., Ader M., Steil G.M. Toward an integrated phenotype in pre-NIDDM. Diabet Med 1996, 13:S67-77.
13. Pietrobelli A., Formica C., Wang Z., Heymsfield S.B. Dual X-ray absorptiometry body composition model: a review of physical concepts. Am J Physiol 1996, 271:E941-951.
14. Thomaseth K., Kautzky-Willer A., Ludvik B., Prager R., Pacini G. Integrated mathematical model to assess beta-cell activity during the oral glucose test. Am J Physiol 1996, 270:E522-531.
15. Patterson B.W., Zhao G., Klein S. Improved accuracy and precision of gas chromatography/mass spectrometry measurements for metabolic tracers. Metabolism 1998, 47:706-712.
16. Wolfe R. Radioactive and stable isotope tracers in biomedicine: principles and practice of kinetic analysis 1992, Wiley-Liss, New York.
17. Breda E., Cavaghan M.K., Toffolo G., Polonsky K.S., Cobelli C. Oral glucose tolerance test minimal model indexes of beta-cell function and insulin sensitivity. Diabetes 2001, 50:150-158.
18. Cobelli C., Toffolo G.M., Dalla Man C. Assessment of beta-cell function in humans, simultaneously with insulin sensitivity and hepatic extraction, from intravenous and oral glucose tests. Am J Physiol Endocrinol Metab 2007, 293:E1-E15.
19. Dalla Man C., Yarasheski K.E., Caumo A. Insulin sensitivity by oral glucose minimal models: validation against clamp. Am J Physiol Endocrinol Metab 2005, 289:E954-959.
20. Barrett P.H., Bell B.M., Cobelli C. SAAM II: Simulation, Analysis, and Modeling Software for tracer and pharmacokinetic studies. Metabolism 1998, 47:484-492.
21. DeFronzo R.A. Lilly lecture 1987. The triumvirate: beta-cell, muscle, liver. A collusion responsible for NIDDM. Diabetes 1988, 37:667-687.
22. Faerch K., Vaag A., Holst J.J., Glumer C., Pedersen O., Borch-Johnsen K. Impaired fasting glycaemia vs impaired glucose tolerance: similar impairment of pancreatic alpha and beta cell function but differential roles of incretin hormones and insulin action. Diabetologia 2008, 51:853-861.
23. Utzschneider K.M., Tong J., Montgomery B. The dipeptidyl peptidase-4 inhibitor vildagliptin improves beta-cell function and insulin sensitivity in subjects with impaired fasting glucose. Diabetes Care 2008, 31:108-113.
24. Bock G., Man C.D., Micheletto F. The effect of DPP-4 inhibition with sitagliptin on incretin secretion and on fasting and postprandial glucose turnover in subjects with impaired fasting glucose. Clin Endocrinol (Oxf) 2009.
25. Muscelli E., Mari A., Casolaro A. Separate impact of obesity and glucose tolerance on the incretin effect in normal subjects and type 2 diabetic patients. Diabetes 2008, 57:1340-1348.
26. Ahren B. Beta- and alpha-cell dysfunction in subjects developing impaired glucose tolerance: outcome of a 12-year prospective study in postmenopausal Caucasian women. Diabetes 2009, 58:726-731.
27. Prigeon R.L., Quddusi S., Paty B., D'Alessio D.A. Suppression of glucose production by GLP-1 independent of islet hormones: a novel extrapancreatic effect. Am J Physiol Endocrinol Metab 2003, 285:E701-E707.
28. Edgerton D.S., Johnson K.M., Neal D.W. Inhibition of dipeptidyl peptidase-4 by vildagliptin during glucagon-like peptide-1 infusion increases liver glucose uptake in the conscious dog. Diabetes 2009, 58(January (1)):243-249.
29. Zheng D., Ionut V., Mooradian V., Stefanovski D., Bergman R.N. Exenatide sensitizes insulin-mediated whole-body glucose disposal and promotes uptake of exogenous glucose by the liver. Diabetes 2009, 58:352-359.